STRO Sutro Biopharma Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of sutrobio.com (STRO)

Sutro Biopharma, Inc. (STRO) is developing precision ADC drugs through cell-free protein synthesis. The EV/Sales multiple demonstrates market interest in the assets, with the metric currently standing at 5798.94. Growth potential is driven by clinical trials of targeted anti-tumor agents and the recruitment of leading oncobiologists who are creating breakthrough medical solutions in high-tech R&D laboratories.

Company Value to Revenue: Sutro Biopharma Inc. (STRO) for 11/23/2025 - 11/20/2026

sutrobio.com - analytical breakdowns and key metrics (STRO)

- share price and consensus valuation forecast:
Initial company analysis:Sutro Biopharma, Inc. STRO
Product sample of Sutro Biopharma, Inc.

As a non-cyclical immuno-oncology business, Sutro Biopharma, Inc. (STRO) demonstrates high macro-resilience, where asset value is driven by clinical achievements and partnerships. By analyzing the EV-to-revenue ratio, an investor assesses the total enterprise value independent of debt load, which reveals the company's actual market stability and the balance between operational reliability and return potential.

Competitor analysis for Sutro Biopharma, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP